CD274 and head and neck squamous cell carcinoma: In head and neck squamous cell carcinoma (HNSCC), ICI treatment is approved in the metastatic setting as second-line treatment [95,96] as well as first-line treatment in combination with chemotherapy and as monotherapy in patients with a PD-L1 CPS ≥ 1 [36].